Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation
- 328 Downloads
Frailty is an important prognostic factor in older adults with cardiovascular diseases. We aim to describe the characteristics of elderly hospitalised frail patients with non-valvular atrial fibrillation (NVAF) and to assess the influence of frailty, along with other functional and health status variables on anticoagulation prescription, 1-year all-cause mortality, and the incidence of ischemic and bleeding complications. An observational, prospective multicentre study was carried out on patients with NVAF over the age of 75, who were admitted to the Internal Medicine departments in Spain. A total of 615 patients were evaluated (mean age 85.23 ± 5.16 years, 54.3% females, 48.3% frail). Frail patients had higher CHA2DS2-VASc and HAS-BLED scores, more comorbidities and worse functional status and cognitive impairment compared to non-frail. During hospitalisation, 58 (9.4%) patients died (12.5% frail, 6.6% non-frail, p = 0.01). Among the participants discharged, 69.8% received anticoagulants, 13% anti-platelets only and 16.9% no anti-thrombotics, with no difference by frailty status. Frailty is not a predictor of anticoagulant prescription at discharge (OR 0.93, 95% CI 0.55–1.57), while functional dependency remains significantly associated (OR for severe dependency 0.44, 95% CI 0.23–0.82). After the 1-year follow-up, frail patients have a higher risk of death (HR 1.99, 95% CI 1.43–2.76). Among patients taking anticoagulants, the incidence of stroke and major bleeding is similar between frailty groups. In our study, frailty is related to worse global health status. It has no impact on antithrombotic prescription, nor is a predictor of AF complications, even though frail subjects have a higher mortality during hospitalisation and after 1-year follow-up.
KeywordsAtrial fibrillation Anticoagulants Aged Frailty Elderly Antithrombotic therapy
We wish to acknowledge all the investigators of the NONAVASC registry for collecting data for the study, and also would like to thank Mr M. Gómez for his kind review of the final draft of the manuscript.
M. Camafort Babkowski, E. Rovira Daudí, E. Jarauta Simón, I. García Polo, J.C. Arévalo Lorido, J. Portillo Sánchez, I. Martínez Moreno, C. de la Guerra Acebal, C. Argüello Martín, SI. Aranda Sánchez, I. Novo Veleiro, M. Pena Seijo, F. Salgado Ordoñez, J.A. Vargas Hitos, J. González Moraleja, NR. Tobares Carrasco, P. Freixas Descarrega, I. Campodarve Botet, C. Fernández Capitán, LM. Palomar Rodríguez, AB. Gómez Belda, D. Chivite Guillén, M.A. Rico Corral, JL. Hernández Hernández, E. Coloma Bazán, X. Sobrino Martínez, J. Grandes Ibáñez, M. Martín Millán, R. Cuenca Acevedo, JB. Pérez Lorenz, A. de la Peña Fernández, G. López Castellanos, E. Montero Hernández, E. Calderón Sandubete, C. Lahoz Rallo, A. de los Santos Moreno, J.A. Martínez Muradas, J. Alfonso Megido, J.I. Cuende Melero, R. Cotos Cancas, JJ. Tamarit García, F. Bonilla Rovira, A. Epalza Bueno, M. Morales Conejo, L. Manzano Espinosa, S. Freire Castro, A. Rodríguez González, M. Menduiña Guillén, A. López Suárez, JF. Sánchez Muñoz- Torrero, M.D. Martín Escalante, JA. Ortiz Minuesa, J.C. Martínez-Acitores, M.B. Alonso Ortiz, D. Filella Agulló, H. Ágreda López, M. Romero Jiménez, ME. Fernández Pérez, J.L. Díaz Díaz, C. Pérez Bocanegra, R. Martínez Fernández, J.A. Nieto Rodríguez, J. Masferrer Serra, L. Mérida Rodrigo, J.M. Varela Aguilar, A. Mujal Martínez, L. Castilla Guerra, P. Castellanos Llauger, G. Tiberio López, E. Guevara Sierra, and J. Fernández Pardo.
The registry website was funded by a non-conditioned grant from Bayer Laboratories.
Compliance with ethical standards
Conflict of interest
None of the authors have had any relationship with industry and financial associations that might pose a conflict of interest with the manuscript.
Statements on human and animal rights
The study is approved by the appropriate institutional research ethics committee. All procedures performed in the study involving human participants are in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
A written informed consent was obtained from all participants included in the study.
- 1.Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14(6):392–397. https://doi.org/10.1016/j.jamda.2013.03.022 PubMedPubMedCentralCrossRefGoogle Scholar
- 2.Martinez-Reig M, Flores Ruano T, Fernandez Sanchez M, Nogueron Garcia A, Romero Rizos L, Abizanda Soler P (2016) Frailty and long term mortality, disability and hospitalisation in Spanish older adults. The FRADEA Study. Rev Esp Geriatr Gerontol 51(5):254–259. https://doi.org/10.1016/j.regg.2016.01.006 PubMedCrossRefGoogle Scholar
- 5.Cacciatore F, Abete P, Mazzella F, Viati L, Della Morte D, D’Ambrosio D, Gargiulo G, Testa G, Santis D, Galizia G, Ferrara N, Rengo F (2005) Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest 35(12):723–730. https://doi.org/10.1111/j.1365-2362.2005.01572.x PubMedCrossRefGoogle Scholar
- 6.Ekerstad N, Swahn E, Janzon M, Alfredsson J, Lofmark R, Lindenberger M, Andersson D, Carlsson P (2014) Frailty is independently associated with 1-year mortality for elderly patients with non-ST-segment elevation myocardial infarction. Eur J Prev Cardiol 21(10):1216–1224. https://doi.org/10.1177/2047487313490257 PubMedCrossRefGoogle Scholar
- 11.Mazzone A, Bo M, Lucenti A, Galimberti S, Bellelli G, Annoni G (2016) The role of comprehensive geriatric assessment and functional status in evaluating the patterns of antithrombotic use among older people with atrial fibrillation. Arch Gerontol Geriatr 65:248–254. https://doi.org/10.1016/j.archger.2016.04.008 PubMedCrossRefGoogle Scholar
- 12.Bo M, Sciarrillo I, Maggiani G, Falcone Y, Iacovino M, Grisoglio E, Fonte G, Grosjean S, Gaita F (2017) Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical inpatients with atrial fibrillation. Geriatr Gerontol Int 17(3):416–423. https://doi.org/10.1111/ggi.12730 PubMedCrossRefGoogle Scholar
- 14.Lefebvre MC, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc Nguyen P, Tannenbaum C (2016) The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol 32(2):169–176. https://doi.org/10.1016/j.cjca.2015.05.012 PubMedCrossRefGoogle Scholar
- 15.Gullon A, Suarez C, Diez-Manglano J, Formiga F, Cepeda JM, Pose A, Camafort M, Castiella J, Rovira E, Mostaza JM (2017) Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at internal medicine departments. NONAVASC registry. Med Clin (Barc) 148(5):204–210. https://doi.org/10.1016/j.medcli.2016.10.042 CrossRefGoogle Scholar
- 16.Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210 PubMedCrossRefGoogle Scholar
- 17.Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137(2):263–272. https://doi.org/10.1378/chest.09-1584 PubMedCrossRefGoogle Scholar
- 29.Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S (2006) Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 37(4):1075–1080. https://doi.org/10.1161/01.STR.0000209239.71702.ce PubMedCrossRefGoogle Scholar
- 31.Sanchez-Barba B, Navarrete-Reyes AP, Avila-Funes JA (2013) Are geriatric syndromes associated with reluctance to initiate oral anticoagulation therapy in elderly adults with nonvalvular atrial fibrillation? J Am Geriatr Soc 61(12):2236–2237. https://doi.org/10.1111/jgs.12582 PubMedCrossRefGoogle Scholar
- 32.Diez-Manglano J, Bernabeu-Wittel M, Murcia-Zaragoza J, Escolano-Fernandez B, Jarava-Rol G, Hernandez-Quiles C, Oliver M, Sanz-Baena S (2017) Oral anticoagulation in patients with atrial fibrillation and medical non-neoplastic disease in a terminal stage. Intern Emerg Med 12(1):53–61. https://doi.org/10.1007/s11739-016-1517-4 PubMedCrossRefGoogle Scholar
- 35.Suarez Fernandez C, Formiga F, Camafort M, Cepeda Rodrigo M, Diez-Manglano J, Pose Reino A, Tiberio G, Mostaza JM (2015) Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord 15:143. https://doi.org/10.1186/s12872-015-0137-7 PubMedPubMedCentralCrossRefGoogle Scholar
- 37.Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P (2012) Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 7(3):e33559. https://doi.org/10.1371/journal.pone.0033559 PubMedPubMedCentralCrossRefGoogle Scholar